Clinical Trials
15
Active:0
Completed:14
Trial Phases
2 Phases
Phase 2:12
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 2
12 (80.0%)Phase 3
3 (20.0%)An Open Label Study to Evaluate G17DT Compared to Gemcitabine
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT03200821
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02521649
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
Phase 2
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02518529
Effect of G17DT in Patients With Stage II/III Colorectal Cancer
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02518373
Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer
Phase 2
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02450032
- Locations
- 🇬🇧
Glasgow Royal Infirmary, Glasgow, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
No news found